Your browser doesn't support javascript.
loading
OSWG Recommended Approaches to the Nonclinical Pharmacokinetic (ADME) Characterization of Therapeutic Oligonucleotides.
Berman, Cindy L; Antonsson, Madeleine; Batkai, Sandor; Bosgra, Sieto; Chopda, Girish R; Driessen, Wouter; Foy, Jeffrey; Hassan, Chopie; Hu, Xiao Shelley; Jang, Hyun Gyung; Sanseverino, Mark; Thum, Thomas; Wang, Yanfeng; Wild, Martin; Wu, Jing-Tao.
Afiliación
  • Berman CL; Berman Consulting, Wayland, Massachusetts, USA.
  • Antonsson M; Early CVRM, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Batkai S; Cardior Pharmaceuticals GmbH, Hannover, Germany.
  • Bosgra S; Independent Consultant, Amsterdam, The Netherlands.
  • Chopda GR; Dicerna Pharmaceuticals, Inc., a Novo Nordisk Company, Lexington, Massachusetts, USA.
  • Driessen W; Anjarium Biosciences AG, Zurich, Switzerland.
  • Foy J; PepGen, Inc., Cambridge, Massachusetts, USA.
  • Hassan C; ProQR Therapeutics NV, Leiden, The Netherlands.
  • Hu XS; Wave Life Sciences, Cambridge, Massachusetts, USA.
  • Jang HG; Wave Life Sciences, Cambridge, Massachusetts, USA.
  • Meena; Stoke Therapeutics, Bedford, Massachusetts, USA.
  • Sanseverino M; Agilent Therapeutics, Boulder, Colorado, USA.
  • Thum T; Cardior Pharmaceuticals GmbH, Hannover, Germany.
  • Wang Y; Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover, Germany.
  • Wild M; Fraunhofer Institute of Toxicology and Experimental Medicine, Hannover, Germany.
  • Wu JT; Formerly of Ionis Pharmaceuticals, Carlsbad, California, USA.
Nucleic Acid Ther ; 33(5): 287-305, 2023 10.
Article en En | MEDLINE | ID: mdl-37590469
This white paper summarizes the recommendations of the absorption, distribution, metabolism, and excretion (ADME) Subcommittee of the Oligonucleotide Safety Working Group for the characterization of absorption, distribution, metabolism, and excretion of oligonucleotide (ON) therapeutics in nonclinical studies. In general, the recommended approach is similar to that for small molecule drugs. However, some differences in timing and/or scope may be warranted due to the greater consistency of results across ON classes as compared with the diversity among small molecule classes. For some types of studies, a platform-based approach may be appropriate; once sufficient data are available for the platform, presentation of these data should be sufficient to support development of additional ONs of the same platform. These recommendations can serve as a starting point for nonclinical study design and foundation for discussions with regulatory agencies.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Oligonucleótidos Tipo de estudio: Guideline Idioma: En Revista: Nucleic Acid Ther Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Oligonucleótidos Tipo de estudio: Guideline Idioma: En Revista: Nucleic Acid Ther Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos